LTRN Jun 2024 9.000 call
| Previous close | 0.4700 |
| Open | 0.9000 |
| Bid | 0.0000 |
| Ask | 0.5000 |
| Strike | 9.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.4600 - 0.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
Business WireLantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
DALLAS, May 09, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024.
Business WireOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
PARIS & DALLAS, May 06, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI)(1) inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its proprietary RADR® AI platform to uncover biomar
Business WireLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
DALLAS, May 02, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2024 financial results webcast on Thursday, May 9, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.
